NovaBridge Biosciences switches auditors to Deloitte

NovaBridge Biosciences changed its independent auditor after the Audit Committee dismissed PricewaterhouseCoopers LLP and appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP, both actions effective June 16, 2026.

Rhea-AI Filing Summary

NovaBridge Biosciences changed its independent auditor after the Audit Committee dismissed PricewaterhouseCoopers LLP and appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP, both actions effective June 16, 2026. PwC’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.

The filing notes there were no disagreements with PwC on accounting, disclosure, or audit procedures, and no reportable events other than previously disclosed material weaknesses in information technology general controls as of December 31, 2025 and 2024. NovaBridge also states it did not consult Deloitte on accounting or audit issues before the appointment. This 6-K is incorporated by reference into the company’s existing Form F-3 and multiple Form S-8 registration statements.

Insights

Audit & Governance Analyst

NovaBridge replaces PwC with Deloitte amid existing IT control weaknesses.

NovaBridge Biosciences’ Audit Committee has replaced PricewaterhouseCoopers with Deloitte as independent auditor, effective for the year ending December 31, 2026. PwC’s prior reports for 2025 and 2024 were clean, without adverse opinions or scope or principle qualifications.

The company highlights no disagreements or additional reportable events with PwC beyond previously disclosed material weaknesses in information technology general controls. Those weaknesses can affect the reliability of financial reporting until remediated, though they were already disclosed in earlier annual reports.

The 6-K is incorporated by reference into NovaBridge’s Form F-3 and several Form S-8 registration statements, so the change in auditor and control context now also apply to those offerings. Future annual reporting for 2026 will reflect Deloitte’s audit approach to these control issues.

Key Figures

PwC audit years: fiscal years 2025 and 2024 New auditor effective year: fiscal year ending December 31, 2026 Form 20-F filing dates: April 7, 2026 and April 3, 2025 +2 more

5 metrics

PwC audit years fiscal years 2025 and 2024 Years for which PwC audited NovaBridge’s consolidated financial statements

New auditor effective year fiscal year ending December 31, 2026 First full year for Deloitte as independent auditor

Form 20-F filing dates April 7, 2026 and April 3, 2025 Dates when material ITGC weaknesses were reported in annual reports

Form F-3 file number 333-286954 Registration statement incorporated by reference

Form S-8 file numbers 333-239871, 333-256603, 333-265684, 333-279842, 333-290195 Equity compensation registrations incorporating this 6-K

Key Terms

independent registered public accounting firm, material weaknesses, information technology general controls, reportable events, +1 more

5 terms

independent registered public accounting firm regulatory

"PwC as the Company’s independent registered public accounting firm, effective immediately."

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

material weaknesses financial

"other than the material weaknesses related to ineffective information technology general controls"

Material weaknesses are significant flaws in a company’s systems for ensuring its financial reports are accurate and reliable. Like a broken lock on a safe, they increase the chance that financial statements contain big errors or omissions, which can mislead investors about performance and risk; discovering one often raises questions about management oversight, may lead to restated results, and can affect investor confidence and a company’s valuation.

information technology general controls technical

"material weaknesses related to ineffective information technology general controls (“ITGCs”) that existed as of December 31, 2025 and 2024"

reportable events regulatory

"and (ii) no reportable events (as that term is described in Item 16F(a)(1)(v) of Form 20-F)"

Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.

incorporated by reference regulatory

"set forth in this Report on Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What auditor change did NovaBridge Biosciences (NBP) disclose in this Form 6-K?

NovaBridge Biosciences’ Audit Committee dismissed PricewaterhouseCoopers LLP and appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP as its independent registered public accounting firm, effective June 16, 2026, covering the fiscal year ending December 31, 2026.

Did PwC issue any adverse opinions on NovaBridge Biosciences (NBP) financial statements?

PwC’s reports on NovaBridge’s consolidated financial statements for the years ended December 31, 2025 and 2024 did not contain adverse opinions, disclaimers of opinion, or qualifications related to uncertainty, audit scope, or accounting principles, according to the company’s disclosure.

Were there disagreements between NovaBridge Biosciences (NBP) and PwC before the dismissal?

The company states there were no disagreements with PwC on accounting principles, financial statement disclosure, or auditing scope or procedures for 2025, 2024, or through June 16, 2026 that would have required reference in PwC’s audit reports.

What material weaknesses did NovaBridge Biosciences (NBP) report regarding internal controls?

NovaBridge previously reported material weaknesses in ineffective information technology general controls as of December 31, 2025 and 2024. These weaknesses were disclosed in Item 15 of its Form 20-F annual reports filed on April 7, 2026 and April 3, 2025, respectively.

Did NovaBridge Biosciences (NBP) consult Deloitte before appointing it as auditor?

The company reports that neither it nor anyone on its behalf consulted Deloitte during 2025, 2024, or through June 16, 2026 on accounting principles, potential audit opinions, disagreements, or reportable events before Deloitte’s appointment.

How is this NovaBridge Biosciences (NBP) 6-K used in existing registration statements?

NovaBridge states the information in this Form 6-K is incorporated by reference into its Form F-3 registration statement and several Form S-8 registration statements, becoming part of those filings from the date the Form 6-K is furnished.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:40 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

Change in Company’s Certifying Accountants

Dismissal of PricewaterhouseCoopers LLP

On June 16, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of NovaBridge Biosciences (“NovaBridge” or the “Company”) approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm, effective immediately.

The reports of PwC on the Company’s consolidated financial statements for the fiscal years ended December 31, 2025 and 2024, did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the fiscal years ended December 31, 2025 and 2024, and the subsequent period through June 16, 2026, there were (i) no disagreements (as that term is described in Item 16F(a)(1)(iv) of Form 20-F), between the Company and PwC on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference to the subject matter of the disagreement in PwC’s reports on the Company’s consolidated financial statements for such years, and (ii) no reportable events (as that term is described in Item 16F(a)(1)(v) of Form 20-F) other than the material weaknesses related to ineffective information technology general controls (“ITGCs”) that existed as of December 31, 2025 and 2024 as reported in Item 15 in the Company’s annual reports on Form 20-F filed with the SEC on April 7, 2026 and April 3, 2025, respectively.

The Company provided PwC with a copy of the disclosures it is making in this Current Report on Form 6-K and requested that PwC furnish it with a letter addressed to the U.S. Securities and Exchange Commission (“SEC”) stating whether or not PwC agrees with the above disclosures and, if not, stating the respects in which PwC does not agree. A copy of PwC’s letter to the SEC, dated June 16, 2026, is attached herewith as Exhibit 16.1 to this Current Report on Form 6-K.

Engagement of Deloitte Touche Tohmatsu Certified Public Accountants LLP

On June 16, 2026, the Audit Committee approved the appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, effective immediately.

During the fiscal years ended December 31, 2025 and 2024, and the subsequent period through June 16, 2026, neither the Company nor anyone on its behalf consulted with Deloitte regarding (i) the application of accounting principles to a specific transaction, either completed or proposed, (ii) the type of audit opinion that might be rendered on the Company’s financial statements and neither a written report nor oral advice was provided to the Company that Deloitte concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issues, (iii) any matter that was the subject of a disagreement (as that term is described in Item 16F(a)(1)(iv) of Form 20-F) of Regulation S-K and the related instructions), or (iv) any reportable event (as that term is described in Item 304(a)(1)(v) of Regulation S-K).

Incorporation by Reference

The information set forth in this Report on Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842 and File No. 333-290195) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
16.1	Letter from Predecessor Auditor

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NovaBridge Biosciences
	By	:	/s/ Xi-Yong Fu
	Name	:	Xi-Yong (Sean) Fu
	Title	:	Chief Executive Officer

Date: June 16, 2026

Filing Exhibits & Attachments

1 document

Other Documents

• EX-16.1 EX-16.1 15.0 KB